FDA Approves SetPoint Neuroimmune Modulation Device for Rheumatoid Arthritis

Follow Drugslib on

By Lori Solomon HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

THURSDAY, Aug. 7, 2025 -- The U.S. Food and Drug Administration has approved the SetPoint System, a neuroimmune modulation device for the treatment of adults living with moderate-to-severe rheumatoid arthritis (RA).

The SetPoint System is indicated for patients who are not adequately managed by -- or cannot tolerate -- existing advanced RA therapies, such as biological and targeted synthetic disease-modifying antirheumatic drugs (DMARDs). The SetPoint System is an implantable, integrated neurostimulation device that delivers electrical stimulation to the vagus nerve, once daily, and is intended to activate the body's innate anti-inflammatory and immune-restorative pathways.

The approval is supported by the results of the RESET-RA study, in which 242 patients were randomly assigned to the SetPoint System or a sham device. The trial met its primary efficacy end point of American College of Rheumatology 20 percent improvement at three months, with improvements seen for response rates and disease activity metrics through 12 months of follow-up. Three-fourths of participants were free of biologic or targeted synthetic DMARDs at 12 months. The device placement procedure and stimulation therapy were well tolerated, with a 1.7 percent rate of related serious adverse events.

"The approval of the SetPoint System highlights the potential of neuroimmune modulation as a novel approach for autoimmune disease, by harnessing the body's neural pathways to combat inflammation," the principal investigator in the RESET-RA study, Mark Richardson, M.D., Ph.D., from Harvard University in Boston, said in a statement. "After implantation during a minimally invasive outpatient procedure, the SetPoint device is programmed to automatically administer therapy on a predetermined schedule for up to 10 years, simplifying care for people living with RA."

Approval of the SetPoint device was granted to SetPoint Medical.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-08-08 12:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords